Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse A Coker

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Opinion on Therapeutic Patents|December 20, 2024
WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)Jesse A Coker, Shaun R Stauffer
Journal of Natural Products|March 12, 2016
Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease PNathan P Lavey, Jesse A Coker, Eliza A Ruben, et al.
Journal of Medicinal Chemistry|July 17, 2020
Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based MethodsDhruba Sarkar, Edward T Olejniczak, Jason Phan, et al.
ACS Chemical Biology|February 16, 2026
Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch VariabilityJesse A Coker, Rong Sun, Paul M Polzer, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
MCL1 may not mediate chemoresistanceKylin A Emhoff, Kunho Chung, Dongmei Zhang, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial AcyldepsipeptidesYangxiong Li, Nathan P Lavey, Jesse A Coker, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney CancerPooneh Koochaki, Biao Qiu, Jesse A Coker, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m <sup>6</sup> A-dependent translational upregulation of ABCB1Elise G Holvey-Bates, Jesse A Coker, Daniel J Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2024
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid HemangioendotheliomaAjaybabu V Pobbati, Ashley Burtscher, Nandini Rajaram Siva, et al.
The EMBO Journal|April 22, 2026
Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolismPooneh Koochaki, Biao Qiu, Jesse A Coker, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Opinion on Therapeutic Patents|December 20, 2024
WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)Jesse A Coker, Shaun R Stauffer
Journal of Natural Products|March 12, 2016
Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease PNathan P Lavey, Jesse A Coker, Eliza A Ruben, et al.
Journal of Medicinal Chemistry|July 17, 2020
Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based MethodsDhruba Sarkar, Edward T Olejniczak, Jason Phan, et al.
ACS Chemical Biology|February 16, 2026
Fragment-Based Development of NSP14 Exonuclease Inhibitors Confounded by Batch-to-Batch VariabilityJesse A Coker, Rong Sun, Paul M Polzer, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
MCL1 may not mediate chemoresistanceKylin A Emhoff, Kunho Chung, Dongmei Zhang, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial AcyldepsipeptidesYangxiong Li, Nathan P Lavey, Jesse A Coker, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney CancerPooneh Koochaki, Biao Qiu, Jesse A Coker, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m <sup>6</sup> A-dependent translational upregulation of ABCB1Elise G Holvey-Bates, Jesse A Coker, Daniel J Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2024
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid HemangioendotheliomaAjaybabu V Pobbati, Ashley Burtscher, Nandini Rajaram Siva, et al.
The EMBO Journal|April 22, 2026
Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolismPooneh Koochaki, Biao Qiu, Jesse A Coker, et al.
Pageof 2